Minireview: Pharmacogenetics and Beyond: The Interaction of Therapeutic Response, β-Cell Physiology, and Genetics in Diabetes
Open Access
- 1 June 2006
- journal article
- review article
- Published by The Endocrine Society in Endocrinology
- Vol. 147 (6) , 2657-2663
Abstract
Defining the molecular genetics of diabetes gives new insight into the underlying etiology and so should help improve treatment. The genetic etiology is now known for most patients with β-cell monogenic diabetes, allowing genetic classification. We review how this genetic knowledge alters treatment. Patients with a glucose-sensing β-cell defect due to glucokinase mutations have regulated, mild, fasting hyperglycemia. Oral hypoglycemic agents or low-dose insulin rarely improve glycemic control. Patients with hepatic nuclear factor-1α (HNF1α) mutations have progressive β-cell deterioration and require treatment. HNF1α patients are 4 times more sensitive to sulfonylureas than matched type 2 diabetic patients. This is partly due to greater insulin secretion, reflecting the fact that the defect in HNF1α deficiency precedes the KATP channel where sulfonylureas act. HNF1β is expressed in pancreatic stem cells before differentiation into endocrine or exocrine cells, so patients with HNF1β mutations have reduced pancreatic development, resulting in early-onset diabetes and exocrine dysfunction. These patients usually rapidly require insulin and are not sensitive to sulfonylureas. Thirty-five to 50% of patients diagnosed with diabetes before 6 months have a mutation in Kir6.2. The mutated KATP channel in these patients does not close in response to increased ATP concentrations, but can be closed when sulfonylureas bind to the sulfonylurea receptor 1 subunit of the channel by an ATP-independent route. These patients are usually insulin dependent, but have excellent glycemic control on high-dose sulfonylureas tablets. In conclusion, the defining of molecular genetic etiology in monogenic diabetes has identified several specific β-cell defects, and these are critical in determining the response to treatment.Keywords
This publication has 40 references indexed in Scilit:
- Activating Mutations in Kir6.2 and Neonatal DiabetesDiabetes, 2005
- Unlocking the secrets of the pancreatic β cell: man and mouse provide the keyJournal of Clinical Investigation, 2004
- Activating Mutations in the Gene Encoding the ATP-Sensitive Potassium-Channel Subunit Kir6.2 and Permanent Neonatal DiabetesNew England Journal of Medicine, 2004
- Neonatal and very-early-onset diabetes mellitusSeminars in Neonatology, 2004
- Molecular Mechanisms and Clinical Pathophysiology of Maturity-Onset Diabetes of the YoungNew England Journal of Medicine, 2001
- Transient neonatal diabetes: widening the understanding of the etiopathogenesis of diabetes.Diabetes, 2000
- An imprinted locus associated with transient neonatal diabetes mellitusHuman Molecular Genetics, 2000
- Identification of 14 new glucokinase mutations and description of the clinical profile of 42 MODY-2 familiesDiabetologia, 1997
- Familial Hyperglycemia Due to Mutations in Glucokinase -- Definition of a Subtype of Diabetes MellitusNew England Journal of Medicine, 1993
- Mild Familial Diabetes with Dominant InheritanceQJM: An International Journal of Medicine, 1974